Un experimental vaccine against malaria, the “Mosquirix”, received the approval of the European Medicines Agency on Friday. A first in the medical world even if the serum is, for the time being, only partially effective.
This is a great first and very good news. Friday July 24, a vaccine against malaria received a "favorable opinion" from the European Medicines Agency (EMA). It is called “Mosquirix” and was created by the pharmaceutical giant GlaxoSmithKline (GSK) to protect young children, mainly in Africa, at high risk for the disease. This is the first time that a vaccine has been designed against a parasite (Plasmodium falciparum, the parasite of malaria) and not against a virus or bacteria.
>> Focus: “Malaria kills a child every 30 seconds"
Do you like the website ?
Access all our Premium content. More than 2000 articles and ebooks